Pemphigus: Clinical Trials

12 trials for Pemphigus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed. 12 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Completed 12
Phase 32Completed 2

Follow Pemphigus: new trials by email Literature Review of Pemphigus trials Research Report on Pemphigus

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
insulin glargine, human insulin, 0.9% Normal Saline - Pemphigus Vulgaris, Skin Erosion
Phase 2CompletedAlexandria University202024-06-222026-03-10
Dexamethasone Solution and Dexamethasone in Mucolox™
dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™ - Oral Lichen Planus, Mucous Membrane Pemphigoid
Phase 2CompletedUniversity of California, San Francisco292020-12-262023-12-15
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
ARGX-113 - Pemphigus Vulgaris, Pemphigus Foliaceus
Phase 2Completedargenx342017-10-182020-12-14
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
PRN1008 - Pemphigus Vulgaris
Phase 2CompletedPrincipia Biopharma, a Sanofi Company422016-01-222023-02-13
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine - Pemphigus
Phase 2CompletedUniversity of Luebeck232008-01-012017-03-13
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
Azathioprine, Prednisone, Placebo - Pemphigus Vulgaris
Phase 2CompletedTehran University of Medical Sciences482008-01-012010-11-30
Use of KC706 for the Treatment of Pemphigus Vulgaris
KC706 - Pemphigus Vulgaris
Phase 2CompletedKemia, Inc202007-11-012008-06-19
Use of Infliximab for the Treatment of Pemphigus Vulgaris
Infliximab, Placebo Comparator - Pemphigus
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)202006-03-012017-12-06
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
Enbrel (Etanercept) - Pemphigus Vulgaris
Phase 2CompletedMassachusetts General Hospital122004-06-012015-06-03
Effect of Anti CD20 in Pemphigus Desease
Mabthera - Pemphigus
Phase 2 / Phase 3CompletedUniversity Hospital, Rouen222003-06-012013-06-18
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
dexamethasone (50mg 1dd6, 3 consecutive days/month) - Pemphigus
Phase 2 / Phase 3CompletedUniversity Medical Center Groningen602001-01-012007-08-30
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
cyclophosphamide, filgrastim - Pemphigus
Phase 2CompletedJohns Hopkins University351999-04-012008-10-02

Narrower conditions

Autoimmune Diseases (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Communicable Diseases (1)  ·  Immune System Diseases (1)  ·  Insulin Resistance (1)  ·  Lichen Planus, Oral (1)  ·  Pemphigoid, Benign Mucous Membrane (1)  ·  Rare Diseases (1)  ·  Skin Diseases (1)

Broader conditions

Skin Diseases, Vesiculobullous (12)  ·  Skin and Connective Tissue Diseases (12)  ·  Autoimmune Diseases (11)  ·  Immune System Diseases (11)  ·  Skin Diseases (11)  ·  Bronchial Diseases (1)  ·  Bronchiolitis (1)  ·  Bronchiolitis Obliterans (1)  ·  Bronchitis (1)  ·  Conjunctival Diseases (1)  ·  Disease Attributes (1)  ·  Eye Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Graft vs Host Disease (1)  ·  Hyperinsulinism (1)

Interventions

Dexamethasone (3)  ·  Azathioprine (2)  ·  Rituximab (2)  ·  Cyclophosphamide (1)  ·  Etanercept (1)  ·  Filgrastim (1)  ·  Infliximab (1)  ·  Insulin (1)  ·  Insulin Glargine (1)  ·  Prednisone (1)  ·  Saline Solution (1)  ·  Solutions (1)  ·  efgartigimod alfa (1)

Sponsors

Alexandria University (1)  ·  Johns Hopkins University (1)  ·  Kemia, Inc (1)  ·  Massachusetts General Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Principia Biopharma, a Sanofi Company (1)  ·  Tehran University of Medical Sciences (1)  ·  University Hospital, Rouen (1)  ·  University Medical Center Groningen (1)  ·  University of California, San Francisco (1)  ·  University of Luebeck (1)  ·  argenx (1)

Countries

United States (5)  ·  France (2)  ·  Germany (2)  ·  Israel (2)  ·  Australia (1)  ·  Croatia (1)  ·  Egypt (1)  ·  Greece (1)  ·  Hungary (1)  ·  Iran (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Ukraine (1)

Top investigators

Victoria Werth, MD (2)  ·  Alessandro Villa, DDS, PhD, MPH (1)  ·  Alexandra B Kimball, MD, MPH (1)  ·  Amit Pandya, MD (1)  ·  Bruce Strober, MD (1)  ·  Carmen I Farid, MB BCh, MD (1)  ·  Cheyda Chams-Davatchi, MD (1)  ·  David Rubenstein, MD, PhD (1)  ·  David Woodley, MD (1)  ·  Detlef Zillikens, MD (1)  ·  E. William St. Clair, MD (1)  ·  Francisco Kerdel, MD (1)  ·  Garnett Kelsoe, DSci (1)  ·  Grant J. Anhalt (1)

Results publications

PMID 16702494, PMID 17687130, PMID 25123295, PMID 34608631, PMID 35663943, PMID 37549933

NIH funding

2015 (1), 2017 (1)